Similar articles

• Antagonism between an antiserotonin-the butanolamide of 1-methyl-lysergic acid--and the effects of a histamine-liberating substance 48/80 B. W. in man.

  SICUTERI F, MICHELACCI S, FRANCHI G. SICUTERI F, et al. Int Arch Allergy Appl Immunol. 1959;15:291-9. doi: 10.1159/000229054. Int Arch Allergy Appl Immunol. 1959. PMID: 14446403 No abstract available.
• Clinical observations with 1-methyl-lysergic acid butanolamide (UML-491) in vascular headache.

  FRIEDMAN AP. FRIEDMAN AP. Angiology. 1960 Aug;11:364-6. doi: 10.1177/000331976001100409. Angiology. 1960. PMID: 13825096 No abstract available.
• Experimental studies with the butanolamide and propanolamide of 1-methyl-lysergic acid.

  GELFAND MD, WEST GB. GELFAND MD, et al. Int Arch Allergy Appl Immunol. 1961;18:286-91. doi: 10.1159/000229179. Int Arch Allergy Appl Immunol. 1961. PMID: 13704268 No abstract available.
• Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide).

  FRIEDMAN AP, LOSIN S. FRIEDMAN AP, et al. Arch Neurol. 1961 Mar;4:241-5. doi: 10.1001/archneur.1961.00450090007002. Arch Neurol. 1961. PMID: 13701987 No abstract available.
• Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine.

  SICUTERI F. SICUTERI F. Int Arch Allergy Appl Immunol. 1959;15:300-7. doi: 10.1159/000229055. Int Arch Allergy Appl Immunol. 1959. PMID: 14446408 No abstract available.